News | Vascular Access | November 18, 2026

Medtronic to Acquire Contego Medical

Acquisition will expand patient access to next-generation carotid therapies.

Medtronic to Acquire Contego Medical

Nov. 16, 2026  — Medtronic has announced that it intends to acquire Contego Medical, a privately held medical device company focused on innovative solutions for carotid artery disease and peripheral thrombectomy.

The acquisition will build on the company’s exclusive U.S. distribution agreement with Contego (announced in January 2025), and advances Medtronic' strategy of pursuing targeted investments that strengthen the company's core franchises. The deal specifically expands the Medtronic portfolio of differentiated carotid technologies, broadening patient access to innovative therapies for carotid artery and peripheral vascular disease.

“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company’s Cardiovascular portfolio. “By pairing Medtronic’s deep clinical expertise in peripheral and neurovascular technologies with Contego’s next-generation treatments backed by strong and consistent clinical data,† we intend to become an undisputed leader in carotid revascularization.”

Carotid artery disease occurs when the carotid arteries, the major blood vessels supplying the brain, become narrowed or blocked. Plaque can then rupture or embolize and lead to a stroke, accounting for about 20% of ischemic strokes.1 While carotid revascularization is intended to reduce stroke risk, embolic debris released during treatment can contribute to procedural stroke risk.2-5 Contego Medical, founded by Ravish Sachar, MD, and Jay Yadav, MD, developed technology designed to address this challenge through integrated embolic protection.

Contego

“Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter,” said Ravish Sachar, MD, founder and chief executive officer of Contego Medical. “We’re proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients.”

The planned acquisition includes Contego's recently FDA-approved Neuroguard IEP* Direct System, a transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the prospective, multicenter PERFORMANCE III study,6 the Neuroguard IEP Direct System demonstrated exceptional outcomes at 30 days:

  • Zero strokes
  • Zero neurological deaths
  • Zero cranial nerve injuries
  • Zero myocardial infarctions

“Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients,” said Linnea Burman, senior vice president and president of Medtronic Neurovascular.  “We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease.”

Beyond carotid revascularization, the acquisition includes Contego’s Excipio* thrombectomy devices, which complement Medtronic’s Liberant thrombectomy system in the treatment of peripheral vascular disease.

Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. 

 

*Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

† First 3-in-1 carotid artery stenting system compared to standalone stents, balloons, and filters. Clinical outcomes claims are based on prospective, multicenter studies and registries evaluating Contego Medical technologies, including the PERFORMANCE I, PERFORMANCE II, PERFORMANCE III, and Paladin studies. Individual study results may vary, and outcomes should not be directly compared across studies.

References

  1. Musialek P et al. Cardiovasc Res. 2023;121(1):13-43. doi:10.1093/cvr/cvad135

  2. Antonius Carotid Endarterectomy, Angioplasty, and Stenting Study Group. Transcranial Doppler monitoring in angioplasty and stenting of the carotid bifurcation. J Endovasc Ther. 2003 Aug;10(4):702-710.

  3. Martin JB, Pache JC, Treggiari-Venzi M, et al. Role of the distal balloon protection technique in the prevention of cerebral embolic events during carotid stent placement. Stroke. 2001 Feb;32(2):479-484.

  4. Ackerstaff RG, Suttorp MJ, van den Berg JC, et al. Prediction of early cerebral outcome by transcranial Doppler monitoring in carotid bifurcation angioplasty and stenting. J Vasc Surg. 2005;41(4):618-624.

  5. Hellings WE, Ackerstaff RG, Pasterkamp G, De Vries JP, Moll FL. The carotid atherosclerotic plaque and microembolisation during carotid stenting. J Cardiovasc Surg (Torino). 2006 Apr;47(2):115-126.

  6. Lyden SP, Mendes RR, Mouawad NJ, Mallios A, Mathews SJ, Pugar CE, et al; PERFORMANCE III Investigators. Thirty-day outcomes following transcarotid artery revascularization with integrated embolic protection: The PERFORMANCE III study. J Vasc Surg. 2026;84(4):951-960.e3. doi:10.1016/j.jvs.2026.05.027.

 

Medtronic Contego

 


Additional Content

News | Peripheral Artery Disease (PAD)

Aug. 25, 2025 ­­­­— Abbott has received CE Mark in Europe for the Esprit BTK Everolimus Eluting Resorbable Scaffold ...

Home August 26, 2026
Home
News | Peripheral Artery Disease (PAD)

July 21, 2026 — Women who experience pregnancy complications face an increased risk of developing peripheral artery ...

Home July 22, 2026
Home
News | Peripheral Artery Disease (PAD)

June 13, 2026 — New research shows that infrainguinal endovascular interventions for peripheral artery disease (PAD) ...

Home June 15, 2026
Home
News | Peripheral Artery Disease (PAD)

June 10, 2026 — New research shows that patients with peripheral artery disease (PAD) who adhere to pre-operative ...

Home June 11, 2026
Home
News | Peripheral Artery Disease (PAD)

Sept. 9, 2025 — Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating ...

Home September 12, 2025
Home
Subscribe Now